Dassault Systems lowered it Q1 2020: the company is now expecting revenue growth in the range of 14%-17%, down from a 20-23% guidance (that includes the acquisition of Medidata). The company has suffered from weaker than expected new license and services revenues. Meanwhile, revenues of Medidata were on a “momentum and license renewals were up too.
We continue to reflect on Capgemini’s acquisition of Altran.
We usually do not comment on the M&A activities of major PLM ISVs. However, Dassault Systèmes’ acquisition of Medidata, an NYC-headquartered ISV specialized in software to manage clinical trials and commercial launches, is worth a thought or two.